These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
127 related items for PubMed ID: 19489232
41. Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma. Mariuzzi GM, Mariuzzi L, Mombello A, Santinelli A, Valli M, Rahal D, Thompson D, Bartels PH. Pathol Res Pract; 1996 May; 192(5):428-36. PubMed ID: 8832747 [Abstract] [Full Text] [Related]
42. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. Bock N, Meden H, Regenbrecht M, Jünemann B, Wangerin J, Marx D. Anticancer Res; 2000 May; 20(1A):119-24. PubMed ID: 10769643 [Abstract] [Full Text] [Related]
45. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000 [Abstract] [Full Text] [Related]
46. The estrogen receptors alpha, beta, and beta cx. Shaaban AM, Speirs V. Clin Cancer Res; 2005 Nov 15; 11(22):8222; author reply 8222-3. PubMed ID: 16299256 [No Abstract] [Full Text] [Related]
48. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM. Cancer Res; 2000 Nov 15; 60(22):6488-95. PubMed ID: 11103818 [Abstract] [Full Text] [Related]
50. Ductal carcinoma in situ: state of the science and roadmap to advance the field. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. J Clin Oncol; 2009 Jan 10; 27(2):279-88. PubMed ID: 19064970 [Abstract] [Full Text] [Related]
51. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast. Rudnicka L, Stachura J. Pol J Pathol; 2000 Jan 10; 51(3):137-43. PubMed ID: 11247396 [Abstract] [Full Text] [Related]
52. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. Cancer Res; 1998 May 01; 58(9):1839-42. PubMed ID: 9581822 [Abstract] [Full Text] [Related]
54. Cytologic characteristics of endocrine ductal carcinoma in situ of the breast. A case report. Yin H, Schinella R. Acta Cytol; 2002 May 01; 46(5):873-6. PubMed ID: 12365222 [Abstract] [Full Text] [Related]
55. Scientists show that invasive breast cancer develops from early cancer cells. Holzman D. J Natl Cancer Inst; 1995 May 17; 87(10):710-1. PubMed ID: 7563144 [No Abstract] [Full Text] [Related]
57. [Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer]. Feng J, Hu LH, Lu J, Li YR, Xie F. Ai Zheng; 2009 Apr 17; 28(4):436-40. PubMed ID: 19622308 [Abstract] [Full Text] [Related]
59. Ductal carcinoma in situ with periductal fibrosis -- is it in reality an invasive carcinoma? Naresh KN, Borges AM. Hum Pathol; 1996 Jul 17; 27(7):744. PubMed ID: 8698323 [No Abstract] [Full Text] [Related]
60. neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. De Potter CR, Schelfhout AM, Verbeeck P, Lakhani SR, Brünken R, Schroeter CA, Van den Tweel JG, Schauer AJ, Sloane JP. Hum Pathol; 1995 Jun 17; 26(6):601-6. PubMed ID: 7774888 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]